A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of BA058 Administered Via a Coated Transdermal Microarray Delivery System (BA058 Transdermal) in Healthy Postmenopausal Women With Osteoporosis

Abaloparatide Transdermal (50 mcg)

Abaloparatide Transdermal (100 mcg)

Abaloparatide Transdermal (150 mcg)

Abaloparatide Injection (80 mcg)

Abaloparatide Placebo

Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months

Percent Change From Baseline in BMD of Total Hip at 6 Months

Percent Change From Baseline in BMD of Forearm at 6 Months

Percent Change From Baseline in Serum Bone-Specific Alkaline Phosphatase (BSAP) at 6 Months

Percent Change From Baseline in Serum Procollagen Type I C Propeptide (PICP) at 6 Months

Percent Change From Baseline in Serum Osteocalcin at 6 Months

Percent Change From Baseline in Serum Procollagen Type I N Propeptide (PINP) at 6 Months

Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (CTXI) at 6 Months

Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months)

Number of Participants With Treatment Emergent Adverse Events (TEAEs) That Occurred During the Study That Were Associated With Vital Sign Changes

Number of Participants With a Clinically Meaningful Abnormal Electrocardiogram (ECG) Test Result

Number of Participants With an Abnormal Clinical Hematology Laboratory Parameter With an Eastern Cooperative Oncology Group (ECOG) Score of Grade 3 or Grade 4

Number of Participants With an Abnormal Clinical Chemistry Laboratory Parameter With an ECOG Score of Grade 3 or Grade 4

Number of Participants With an Abnormal Clinical Coagulation Laboratory Parameter With an ECOG Score of Grade 3 or Grade 4